Donepezilhydrochloride
Donepex contains the active substance donepezil hydrochloride, which is a reversible inhibitor of acetylcholinesterase, the main enzyme that breaks down acetylcholine in the brain. Donepex is indicated for the symptomatic treatment of mild to moderate Alzheimer's disease.
Particular caution should be exercised:
Before starting to take Donepex, the patient should discuss it with their doctor or pharmacist if they:
The patient should tell their doctor or pharmacist about all medicines they are taking or have recently taken, as well as any medicines they plan to take. It is particularly important to inform the doctor about taking any of the following medicines:
A patient who is to undergo anesthesia should inform their doctor that they are taking Donepex.
Food does not affect the absorption of the medicine. The patient should not consume alcohol while taking Donepex.
In pregnancy, during breastfeeding, or if the patient suspects they are pregnant, or plans to become pregnant, they should consult a doctor or pharmacist before taking this medicine. The use of Donepex during pregnancy is contraindicated. Women taking Donepex should not breastfeed.
Donepex has a minor or moderate effect on the ability to drive or operate machines. Alzheimer's disease may impair the ability to drive or operate machines. Additionally, Donepex may cause fatigue, dizziness, and muscle cramps, especially at the beginning of treatment or after increasing the dose. The doctor will assess the patient's ability to continue driving or operating machines while taking Donepex.
If the patient has been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
This medicine should always be taken according to the doctor's instructions. In case of doubts, the patient should consult their doctor or pharmacist.
The initial dose is 5 mg per day (taken once a day). The patient should continue taking 5 mg per day for at least one month, which will allow the doctor to assess the effectiveness of the treatment. After a clinical assessment of the therapy for one month at a dose of 5 mg per day, the doctor may increase the dose of the medicine to 10 mg per day (taken once a day). The maximum recommended daily dose is 10 mg. The tablets should be taken orally, in the evening, just before bedtime. If the patient experiences unusual dreams, nightmares, or difficulty falling asleep (see section 4), the doctor may recommend taking Donepex in the morning. If the patient feels that the effect of Donepex is too strong or too weak, they should consult their doctor.
The use of Donepex in children is not recommended.
Patients with impaired renal function may use a similar dosing schedule as patients with normal renal function.
In patients with mild and moderate hepatic impairment, the dose should be increased according to individual patient tolerance. There are no data on the use of the medicine in patients with severe hepatic impairment.
In case of overdose, the patient should immediately inform their doctor or go to the nearest hospital. Symptoms suggesting overdose may include: severe nausea, vomiting, salivation, excessive sweating, bradycardia (slow heart rate), hypotension, respiratory depression, collapse, and seizures. Progressive muscle weakness leading to death may also occur in the case of respiratory muscle weakness. Depending on the symptoms, the doctor will provide appropriate treatment.
The patient should take the missed dose as soon as possible, unless it is close to the time of the next dose. In this case, they should take the next dose at the scheduled time. The patient should not take a double dose to make up for the missed dose.
Like all medicines, Donepex can cause side effects, although not everybody gets them.
If any of the following severe side effects occur, the patient should immediately consult a doctor, as they may require urgent medical attention:
Other side effects include:
Common side effects (may occur in less than 1 in 10 patients):
Uncommon side effects (may occur in less than 1 in 100 patients):
Rarely reported side effects (may occur in less than 1 in 1,000 patients):
Unknown frequency (cannot be estimated from available data)
Reporting side effects
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month. Store in the original packaging.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
core: microcrystalline cellulose, lactose monohydrate, cornstarch, hypromellose, magnesium stearate, coating: Opadry HP White (macrogol, titanium dioxide (E171), talc, polyvinyl alcohol), yellow lake quinoline (E104). Each Donepex 10 mg coated tablet contains 10 mg of donepezil hydrochloride.
Donepex 5 mg is a yellow, round, biconvex coated tablet. Donepex 10 mg is a white, round, biconvex coated tablet. Available packs: 28 tablets of 5 mg or 10 mg in a polyethylene container with a polypropylene screw cap and a desiccant in the container or PVC/PVDC/Aluminum blisters in a cardboard box.
Celon Pharma S.A. ul. Ogrodowa 2A 05-092 Łomianki/Kiełpin tel.: (22) 75-15-933, e-mail: info@celonpharma.com
Celon Pharma S.A. ul. Marymoncka 15 05-152 Kazuń Nowy For more detailed information about this medicine, the patient should contact the marketing authorization holder: Celon Pharma S.A. ul. Ogrodowa 2A, Kiełpin 05-092 Łomianki tel.: (22) 75-15-933, e-mail: info@celonpharma.com To protect the medicine from unauthorized access and children, the packaging cap is equipped with a tamper-evident ring and a child-resistant opening mechanism. The patient should follow the instructions below to open the packaging correctly: PRESS THE CAP FIRMLY TURN THE PRESSED CAP HALF A TURN
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.